Dispatch · Palo Alto / Helsinki · Vol. I
Avenue
Avenue
Biosciences.
Inside the transatlantic biotech rewriting how cells fold, modify, and ship the proteins that become medicines.
Inside the transatlantic biotech rewriting how cells fold, modify, and ship the proteins that become medicines.
It is a Tuesday in Helsinki. On Arabiankatu - Arabia Street, named for the old porcelain works - a bench scientist queues a 96-well plate into a robot. Each well holds a different signal peptide. Each peptide is a tiny address label telling the cell where to send a protein next. By Friday, the team in Palo Alto will know which addresses worked, which didn't, and which one will earn a customer their next manufacturing milestone. This is Avenue Biosciences, the only protein engineering company in the world spending its days inside the cell's shipping department.
Most biotech optimizes what a drug does. Avenue optimizes how the factory delivers it. The result is the same molecule, more of it, more cheaply, more reliably. For a $400B biologics industry that loses money every time a fermenter underperforms, that is not a small thing.
The secretory pathway is the route every cell uses to ship its own proteins outward - through the endoplasmic reticulum, the Golgi, into a vesicle, out the door. Biopharma has spent forty years using that pathway to make biologics. It has spent almost none of that time engineering it. Avenue's platform changes that. The company couples high-throughput chemistry with synthetic biology and an in-house machine learning stack to test thousands of natural and synthetic signal peptides at once - and predict which one will move a particular protein out of the cell most efficiently.
The output is unglamorous and lucrative: more grams of protein per liter of bioreactor. Better folding. Fewer aggregates. A monoclonal antibody that yields a third more product. A biosimilar that finally clears its quality threshold. An mRNA-encoded therapy whose payload actually leaves the cell intact. The customers - drug developers, biosimilar makers, tool companies - care about one number: cost per gram. Avenue moves it.
A catalogue of natural and ML-designed peptides. Each one a different address label, ranked by performance.
Proprietary tools that tune how host cells fold, glycosylate, and export recombinant proteins.
Custom engineering runs with biopharma customers to crack their hardest-to-produce proteins.
Avenue Biosciences traces back to a post-doctoral collaboration at Stanford and UCSF, which became a decade of research at the University of Helsinki, which became a company. The team is technical, transatlantic, and on its founders' third or fourth try at this.
MD/PhD, serial life-science founder with prior exits. Runs commercial and capital from Palo Alto.
Protein science PI at the University of Helsinki. The lab the platform came out of bears his name.
PhD, eMBA. Twenty years of protein biology across academia and biotech.
Scientific lead bridging chemistry, biology, and computation.
Spinout. Avenue Biosciences incorporates as a University of Helsinki spinout, supported by Helsinki Innovation Services.
$2.5M Seed. Voima Ventures leads. Inventure and US angels follow. The platform leaves the academic bench.
Platform scale-up. First commercial partnerships. Team grows. Palo Alto presence formalises at 2627 Hanover Street.
$5.7M Seed Extension. Balnord and Tesi co-lead. Voima Ventures, Inventure, University of Helsinki Funds, and Dimerent all return.
BIO 2026. Selected for the BIO International Convention startup program. 21 people. Counting.
Bring a sequence that won't express well. Walk away with a signal peptide and host configuration that does.
Tune the secretory pathway so post-translational modifications land where regulators want them.
For proteins that have never expressed at scale, screen thousands of peptide-host combos at once.
Same fermenter. Same media. More product. The unglamorous lever drug developers actually pay for.
There is no shortage of AI-protein-design companies. Absci, Cradle, Generate Biomedicines and Dyno all sell some version of "machine learning meets biology." Most of them optimise the protein itself - the sequence, the binding pocket, the activity. Avenue picks a different fight. It optimises everything around the protein: the cell, the address label, the pathway. The result is a complement, not a substitute. A customer can buy a sequence from one platform and a signal peptide from Avenue. That positioning is unusual, and it is deliberate.
A Nordic-heavy cap table with a Helsinki-Stanford spine. Two rounds. Five repeat investors out of six.
Seed lead. Nordic deep-science specialist.
Co-lead of the seed extension. The Finnish state-backed investor.
Co-lead of the seed extension.
Pan-Nordic early stage. Re-upped.
The originating institution still holds equity.
Specialist follow-on.
It is still a Tuesday in Helsinki. The 96-well plate is now a stack of plates. The robot is on its third run of the morning. In Palo Alto, twelve time zones into Monday afternoon, the data is already landing on a slack channel, ranked, and being sent to a customer who wanted a yield bump on a monoclonal antibody by quarter end. They will get it. The team in Arabiankatu will not be on that customer call. They will be on the next plate.
That is the Avenue Biosciences week. Quiet, repeated, compounding. The thesis is not loud and the company is not large. But the bottleneck is real, the science is published, the customers exist, and the people who study where biologics manufacturing breaks have been watching this space for years. The pathway has had a long wait for someone to take it seriously. It now has a tenant.